An update on randomized clinical trials in localized and locoregional prostate cancer (Q36194238)

12 August 2017

1 reference

title

An update on randomized clinical trials in localized and locoregional prostate cancer (English)

1 reference

12 August 2017

1 reference

David F Penson

1

0 references

publication date

1 July 2005

1 reference

12 August 2017

1 reference

12 August 2017

23

1 reference

12 August 2017

4

1 reference

12 August 2017

280-288

1 reference

12 August 2017

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

The influence of finasteride on the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

SELECT: the selenium and vitamin E cancer prevention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Design of the Prostate Cancer Prevention Trial (PCPT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

The prevention of prostate cancer--the dilemma continues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Quality of life after radical prostatectomy or watchful waiting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Hormonal treatment before radical prostatectomy: a 3-year followup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

An opportunity to determine optimal treatment of pT3 prostate cancer: the window may be closing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.05.006

10.1016/J.UROLONC.2005.05.006

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16018945